Detalhe da pesquisa
1.
Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
J Med Virol
; 88(5): 798-806, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412111
2.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet
; 378(9787): 229-37, 2011 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21763935
3.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet
; 378(9787): 238-46, 2011 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21763936
4.
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrob Agents Chemother
; 54(2): 718-27, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19933797
5.
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Antivir Ther
; 14(1): 103-9, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19320243
6.
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Antivir Ther
; 19(8): 819-23, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24704709
7.
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
AIDS Res Hum Retroviruses
; 28(5): 437-46, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21902621
8.
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
J Acquir Immune Defic Syndr
; 60(1): 33-42, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22343174
9.
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
AIDS
; 24(1): 55-65, 2010 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-19926964
10.
11.
12.
13.
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
Artigo
em Inglês
| ARCA | ID: arc-30156